PFIZER, INC.

(PFE)
  Report
Real-time Estimate Cboe BZX  -  05/25 04:04:43 pm EDT
53.40 USD   -0.02%
12:33pPfizer to offer low-cost medicines, vaccines to poor nations
AQ
12:17pGLOBAL MARKETS LIVE : Glencore, Starbucks, Apple, Lyft, Intuit...
10:47aPfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod's Potentially Best-in-Class Profile in Ulcerative Colitis
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Pfizer Inc - U.S. FDA Approves Pfizer's CIBINQO (abrocitinib) for Adults with Moderate-to-Severe Atopic Dermatitis

01/17/2022 | 09:18am EDT

NEW YORK - Pfizer Inc. (NYSE: PFE) announced that the United States (U.S.) Food and Drug Administration (FDA) approved CIBINQO (abrocitinib), an oral, once-daily, Janus kinase 1 (JAK1) inhibitor, for the treatment of adults living with refractory, moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.

CIBINQO is approved at the recommended doses of 100 mg and 200 mg, with the 200 mg dose being recommended for patients who are not responding to the 100 mg dose. Additionally, a 50 mg dose was approved to treat moderate-to-severe AD specifically in patients with moderate renal impairment (kidney failure), certain patients receiving treatment with inhibitors of cytochrome P450 (CYP) 2C19, or patients who are known or suspected to be poor metabolizers of CYP2C19. For patients with moderate renal impairment who are not responding to 50 mg once daily, 100 mg once daily may also be prescribed.

'The reality for patients living with chronic inflammatory skin disease such as moderate-to-severe atopic dermatitis is that many experience debilitating symptoms that are not managed by current treatment options. Today's approval of CIBINQO will provide an important new oral option that could help those who have yet to find relief,' said Jonathan Silverberg, MD, PhD, MPH, Department of Dermatology, The George Washington University School of Medicine and Health Sciences. 'In multiple large-scale clinical trials, CIBINQO demonstrated strong efficacy at clearing skin, improving itch, and managing the extent and severity of eczema, offering a benefit-risk profile that supports the use of this treatment in the FDA-approved patient population.'

The FDA approval was based on results of five clinical trials from a large-scale clinical trial program of more than 1,600 patients. The safety and efficacy of CIBINQO was evaluated in three randomized, placebo-controlled, Phase 3 trials. Additionally, safety was evaluated through a randomized, placebo-controlled, dose-ranging trial and an ongoing long-term open-label extension trial. Across the trials, CIBINQO demonstrated a consistent safety profile and profound improvements in skin clearance, extent of disease, and severity, as well as rapid improvement in itch after two weeks, for some people living with AD versus placebo. In addition, a higher proportion of subjects treated with CIBINQO in two monotherapy trials achieved improvement in itching at week 12 compared to placebo.

'The FDA's approval offers hope to the millions of patients across the U.S. who are suffering daily with an immuno-inflammatory condition that can cause intense and persistent itching, pain, discomfort, and distress if left uncontrolled,' said Mike Gladstone, Global President of Pfizer Inflammation & Immunology. 'CIBINQO, an efficacious once-daily pill, is a medical breakthrough made possible by Pfizer researchers and the people living with moderate-to-severe atopic dermatitis who participated in our clinical trials.'

'Atopic dermatitis is so much more than just a rash, and it goes beyond the surface of the skin. It's a chronic condition that can both significantly disrupt patients' daily lives and negatively impact their emotional well-being,' said Julie Block, President and CEO, National Eczema Association. 'We appreciate Pfizer's commitment to this resilient patient community and eagerly await the positive impact CIBINQO could have on the treatment landscape for moderate-to-severe atopic dermatitis.'

The most common adverse events reported in ?5% of patients with CIBINQO included nasopharyngitis (12.4% with CIBINQO 100 mg, 8.7% with CIBINQO 200 mg, and 7.9%, with placebo), nausea (6%, 14.5%, and 2.1%, respectively), and headache (6%, 7.8%, and 3.5%, respectively).

CIBINQO will be made available in the coming weeks.

Additional Details on the CIBINQO Clinical Trial Program

Five clinical trials in the CIBINQO JAK1 Atopic Dermatitis Efficacy and Safety (JADE) global development program were included in the New Drug Application (NDA) to support the FDA approval.

The safety and efficacy of CIBINQO was evaluated in three Phase 3, randomized, placebo-controlled clinical trials. The trials evaluated measures of improvements in skin clearance, itch, disease extent, and severity, including the Investigator Global Assessment (IGA), Eczema Area and Severity Index (EASI), and Peak Pruritus Numerical Ratings Scale (PP-NRS). In each of the trials, over 40% of patients had prior exposure to a systemic therapy:

JADE MONO-1 and JADE MONO-2: A pair of randomized, double-blind, placebo-controlled trials designed to evaluate the efficacy and safety of two doses (100 mg and 200 mg once daily) of CIBINQO monotherapy in 778 patients 12 years of age and older with moderate-to-severe AD. The trials assessed the co-primary endpoints of IGA and EASI-75 responses at Week 12.

JADE COMPARE: A randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of two doses (100 mg and 200 mg once daily) of CIBINQO in 837 adult patients with moderate-to-severe AD on background topical medicated therapy. The trial also included an active control arm with dupilumab, a biologic treatment administered by subcutaneous injection, compared with placebo. The trial assessed the co-primary endpoints of IGA and EASI-75 responses at Week 12.

Select findings for CIBINQO 100 mg, 200 mg, and placebo follow (*p

(C) 2022 Electronic News Publishing, source ENP Newswire

All news about PFIZER, INC.
12:33pPfizer to offer low-cost medicines, vaccines to poor nations
AQ
12:17pGLOBAL MARKETS LIVE : Glencore, Starbucks, Apple, Lyft, Intuit...
10:47aPfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod's Potentially Best-in-..
AQ
10:19aWALL STREET STOCK EXCHANGE : Investors are eagerly awaiting the Fed minutes
10:02aPfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare ..
BU
08:36aPFIZER INC : Goldman Sachs reiterates its Neutral rating
MD
07:33aPfizer Launches Initiative to Sell Medicines, Vaccines to 45 Low-Income Countries on a ..
MT
06:29aMARKETSCREENER'S WORLD PRESS REVIEW : May 25, 2022
06:00aDavos updates | Zelenskyy says Ukraine won't give up land
AQ
03:37aPfizer to Make Patented Treatments Available at Cost in Lower-Income Countries
MT
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2022 104 B - -
Net income 2022 35 662 M - -
Net cash 2022 15 298 M - -
P/E ratio 2022 8,91x
Yield 2022 3,04%
Capitalization 300 B 300 B -
EV / Sales 2022 2,74x
EV / Sales 2023 3,65x
Nbr of Employees 79 000
Free-Float 58,2%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 53,41 $
Average target price 57,66 $
Spread / Average Target 7,96%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
David M. Denton Chief Financial Officer & Executive Vice President
Mikael Dolsten Executive VP, President-Research & Development
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.-9.55%299 678
JOHNSON & JOHNSON6.04%477 336
ROCHE HOLDING AG-12.57%281 309
ELI LILLY AND COMPANY10.77%275 413
ABBVIE INC.10.13%263 494
NOVO NORDISK A/S1.61%244 637